Pascal Deschatelets - Jun 8, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Scientific Officer
Signature
/s/ David Watson, attorney-in-fact for Pascal Deschatelets
Stock symbol
APLS
Transactions as of
Jun 8, 2022
Transactions value $
-$479,685
Form type
4
Date filed
6/9/2022, 05:23 PM
Previous filing
May 2, 2022
Next filing
Jun 22, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $32K +12K +1.35% $2.67* 904K Jun 8, 2022 Direct F1
transaction APLS Common Stock Sale -$529K -12K -1.33% $44.09 892K Jun 8, 2022 Direct F1
transaction APLS Common Stock Options Exercise $17.4K +6.5K +0.73% $2.67* 898K Jun 8, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -12K -3.29% $0.00 353K Jun 8, 2022 Common Stock 12K $2.67 Direct F1, F3
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -6.5K -1.84% $0.00 346K Jun 8, 2022 Common Stock 6.5K $2.67 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is a scheduled exercise and sale from a 10B5-1 trading plan.
F2 This is a scheduled exercise from 10B5-1 trading plan.
F3 This stock option was granted on 12/5/2013 and is fully vested.